Alnylam announces results from ALN-VSP Phase We study on liver cancers Alnylam Pharmaceuticals.

Related StoriesStudy shows uncommon HER2 missense mutations usually do not spread breast cancer on the ownCrucial change in solitary DNA base predisposes kids to aggressive form of cancerCornell biomedical engineers develop 'super natural killer cells' to destroy cancer cells in lymph nodes Both primary liver cancer and metastatic disease of the liver are associated with poor prognosis for patients, and new therapies are clearly needed, said Josep Tabernero, M.D., Chairman of the Medical Oncology Phase and Section I Program at Vall d’Hebron University Hospital in Barcelona, Spain.Volunteers were thought to have a sleep problem if they verified that they often suffer from insomnia or if they purchased prescription sleeping pills within the last 12 weeks. Of those categorized as having a sleep disturbance, 82.8 % affirmed that they both suffered from insomnia and used sleep medication. Related StoriesDiabetes avoidance begins in the wombMayo Clinic investigators discover novel mechanism linked to diabetes riskDiabetes drug liraglutide ineffective in individuals with advanced center failureUsing this data, researchers calculated an inverse romantic relationship between blue light transmitting and the risk of experiencing sleep disturbances: the lower the blue light transmitting into the retina because of a yellowing of the attention lens, the higher the risk of rest disturbances.